

Supplementary files

Table of contents:

- Supplementary methods	p2
- Supplementary results	P4
- Table S1: Demographics and acute illness at baseline for complete cases (T0 and T3)	P5
- Table S2: Symptoms at three months in cases compared to controls	P6
- Figure S1	p9
- Figure S2	p10
- Figure S3	p11
- Figure S4	p12
- Figure S5	p13
- Table S3: Demographics and acute illness at baseline stratified by vaccination status	p14
- References	p15

SUPPLEMENTARY METHODS

Vaccination status

Full vaccination at baseline required either one dose of Ad26.COV2.S ‘Janssen’ vaccine at least 28 days prior to a positive test or study enrolment; two doses of BNT162b2 ‘Pfizer/BioNTech’; mRNA-1273 90 ‘Moderna’, or ChAdOx1 ‘Astra Zeneca’ vaccines or a combination of one of these at least 14 days prior to a positive test or study enrolment. Participants were also considered fully vaccinated if they received one vaccination dose at least 14 days prior to a positive test or study enrolment and had had a SARS-CoV-2 infection more than eight weeks before the vaccination. Due to the short time window between date of vaccination and study enrolment in the participants, waning immunity was not taken into account. All other participants that received one or more doses of either vaccine at baseline were regarded *partially vaccinated* – including those that were infected within the 14-day or 28-day immunisation period of the vaccine. Participants were categorized as *unvaccinated* in case no vaccine against SARS-CoV-2 was recorded at baseline.

Predefined confounders and comparison between groups

To perform indirect standardization of the primary outcomes with respect to the cases we formed strata using the predefined confounders age (18-45 (young), 46-65 (middle), >65 (old), sex (male and female), educational level (low, median and high) and number of comorbidities (0, 1-2 and >2 comorbidities). For every stratum and group (case and controls) we determined a sample mean and variance, and pooled these to an overall mean and variance of the mean. The overall mean is weighted to the relative size of the stratum (mean) and the square of the relative size (variance of the mean) within the cases. Subsequently, normal approximations from the pooled variances of the mean were used to compute the 95% confidence intervals. We performed permutation tests based on the sum statistic in order to compare symptom prevalence and severity scores between cases and controls, controlling for the same confounders as for the indirect standardization.^{1,2} Strata were omitted from testing when containing subjects from one group only, which led to lower sample sizes.

Permutation tests were also used to assess the effect of vaccination before infection on the prevalence of the significantly elevated symptoms in cases, again taking into account age, co-morbidity, sex and education as predefined confounders. Permutation tests were chosen over regression models because of their non-parametric nature: they do not depend on strong assumptions on a functional form, distribution of the response or the error structure to gain full control of type I error. Permutation tests are considered exact tests because they guarantee that the probability of a type I error is exactly equal to the significance level, as chosen by the researcher. They are therefore considered powerful and useful for many situations.³ Regression models, on the other hand, often

have a series of assumptions and can only approximate the probability of type I error. If the assumptions are strongly violated this approximation may be imprecise.

Scenarios for substitution of missing values at T3

1. Worst case; including all participants that completed T0, assuming participants that missed T3 had all symptoms reported and all severity scores above cut-off.
2. Best case; including all participants that completed T0, assuming all participants that missed T3 had NO symptoms reported, and NO severity scores above cut-off.
3. Carry forward; including all participants that completed T0, carrying forward the T0 value for all symptoms and severity scores cut-off values to T3.
4. Multiple imputation; multiple imputation was performed with 5 imputations after which data were pooled according to Rubin's rules.

Multiple imputation

Multiple imputation was performed with 5 imputations after which data were pooled according to Rubin's rules, using sex, age group, level of education, number of comorbidities and type of participant (case, test-negative control, population control) as predicting variables.

R packages

We used Multivariate Imputation by Chained Equations (MICE) package⁴ for the multiple imputations and COIN package for the permutation tests¹.

SUPPLEMENTARY RESULTS

Description of symptoms at T0 and T3

At study enrolment (T0), 98.1% of cases, compared to 99.7% of test-negatives and 42.2% of population controls reported one or more symptoms; respectively 82.9%, 61.8% and 10.2% reported four or more symptoms (**Table S3**). In the test-negative control group, many participants presented with acute symptoms at T0, which to a large extent had decreased at T3. For the population control group symptom prevalence was largely stable between T0 and T3.

Selection of symptoms significantly elevated

The selection of the symptoms significantly elevated in cases was solely based on a complete case analysis scenario – not taking into account missing data at three months. In case the alternative scenarios used for substituting missing data would have been used for this selection of symptoms, the larger sample size would likely have resulted in an extended list of symptoms– making it less conservative compared to the complete case scenario.

Vaccination status

Of cases, 72.3% (1612) of cases were fully vaccinated at baseline, compared to 76.7% (1294) of test-negatives and 87.0% (3166) of population controls (**table 1**). Respectively, 9.7% (868), 5.9% (99) and 3.2% (116) were partially vaccinated. Differences in vaccination status between cases and controls are explained by timing of recruitment in the population controls and by the vaccination strategy in the Netherlands which initially targeted the older population.

Of cases fully vaccinated, the majority (67.2%) was vaccinated with a Pfizer vaccine, 19.9% with AstraZeneca, 13% with Janssen, 7.5% with Moderna. For the cases that were partially vaccinated, most received a Janssen (51.8%) or Pfizer (38.1%) vaccine (**table S3**). Cases that were fully vaccinated were older (median 51.7 [IQR 40-63] compared to cases that were partially (40.9 [29-49] or unvaccinated (37.8 [27-53]) (**table S3**).

Table S1: Demographics and acute illness at baseline for complete cases (T0 and T3)

	Cases	Test-negative controls	Population controls
N	6,614	1,330	2,445
Age, median [IQR]	51.95 [39.80, 62.59]	57.37 [44.26, 66.28]	53.58 [42.65, 60.99]

Sex, % (n)			
F	63.3 (4185)	64.1 (853)	68.1 (1664)
M	36.5 (2415)	35.4 (471)	31.7 (776)
Other	0.2 (14)	0.4 (6)	0.2 (5)
Pregnancy, % (n)	2.2 (41)	0.8 (2)	4.2 (24)
BMI, mean (SD)	25.73 (4.58)	25.91 (4.78)	25.90 (4.66)
Smoking, % (n)			
Current smoker	4.4 (289)	7.6 (101)	5.7 (139)
Former smoker	25.5 (1687)	29.8 (396)	21.3 (521)
Never smoker	67.5 (4462)	59.3 (789)	71.0 (1735)
Level of education, % (n)			
Low	3.4 (222)	2.0 (26)	5.6 (136)
Median	35.1 (2323)	25.9 (345)	38.8 (948)
High	61.5 (4069)	72.1 (959)	55.7 (1361)
History with COVID-19, % (n)	9.0 (598)	0.0 (0)	0.0 (0)
Nr of comorbidities, % (n)			
0	47.2 (3119)	40.6 (540)	54.0 (1320)
1-2	42.5 (2811)	42.6 (566)	36.5 (893)
>2	10.3 (684)	16.8 (224)	9.5 (232)
Respiratory disease, % (n)	16.6 (1095)	21.0 (279)	11.0 (270)
Hypertension, % (n)	12.0 (794)	15.1 (201)	11.0 (268)
Diabetes, % (n)	2.9 (192)	3.6 (48)	3.5 (86)
Cardiovascular disease, % (n)	2.0 (130)	2.8 (37)	1.4 (35)
Use of healthcare, % (n)*	10.9 (724)	11.5 (153)	5.6 (138)
Medication use, % (n)	77.5 (5124)	68.5 (911)	22.1 (540)
Admitted to hospital, % (n)*	0.1 (8)	0.1 (1)	0.6 (6)
Vaccination status at T0, % (n)			
Fully vaccinated	75.5 (4902)	78.8 (1043)	88.3 (2122)
Partially vaccinated	8.3 (542)	4.9 (65)	2.6 (62)
Unvaccinated	16.2 (1049)	16.3 (216)	9.1 (219)

Table S2: symptoms at three months in cases compared to controls

	Complete case analysis (n=)			Complete case analysis (n=10389)		
	T0			T3		
	Cases, % (95 CI)	Test-negative controls, % (95 CI)	Population controls % (95 CI)	Cases, % (95 CI)	Test-negative controls, % (95 CI)	Population controls % (95 CI)
Nr of symptoms, median [IQR]	9.00 [6.00, 13.00]	6.00 [3.00, 8.00]	0.00 [0.00, 2.00]	2.00 [0.00, 4.00]	1.00 [0.00, 3.00]	0.00 [0.00, 3.00]
Number of symptoms, n (%)						
0	1.9 (171)	0.3 (5)	57.8 (2143)	35.5 (2348)	42.6 (566)	53.8 (1316)
1-2	4.8 (442)	14.4 (245)	21.4 (794)	24.8 (1642)	27.3 (363)	20.7 (507)
3-4	10.3 (942)	23.5 (399)	10.5 (391)	15.4 (1020)	13.5 (179)	11.7 (285)
>4	82.9 (7561)	61.8 (1049)	10.2 (380)	24.3 (1604)	16.7 (222)	13.8 (337)
Fatigue	59.9 (58.9- 60.8)	41.0*** (38.4- 43.5)	13.0*** (11.9- 14.2)	31.1 (30.0-32.2)	19.3*** (17.0-21.6)	16.2*** (14.7-17.7)
Loss of smell	42.5 (41.5- 43.5)	5.7*** (4.4- 7.0)	0.8*** (0.4- 1.1)	12.0 (11.2-12.8)	1.2*** (0.6-1.8)	1.8*** (1.2-2.3)
Dyspnoea	30.2 (29.3- 31.1)	19.6*** (17.6- 21.7)	3.6*** (3.0- 4.3)	16.4 (15.5-17.3)	7.0*** (5.6-8.5)	7.0*** (5.9-8.1)
Difficulty concentrating	15.5 (14.7- 16.2)	8.2*** (6.7- 9.6)	3.8*** (3.2- 4.5)	15.0 (14.1-15.8)	6.3*** (4.9-7.8)	5.7*** (4.7-6.7)
Difficulties in busy environment	12.4 (11.8- 13.1)	7.2*** (5.9- 8.6)	4.3*** (3.6- 5.0)	13.1 (12.4-13.9)	5.7*** (4.3-7.1)	4.7*** (3.8-5.6)
Loss of taste	37.5 (36.5- 38.5)	5.4*** (4.1- 6.6)	0.5*** (0.2- 0.7)	7.1 (6.5-7.7)	0.8*** (0.3-1.3)	1.3*** (0.8-1.9)
Problems with memory†	2.4 (2.1- 2.7)	1.4*** (0.8- 2.0)	1.7* (1.2- 2.1)	8.9 (8.2-9.5)	2.6*** (1.6-3.5)	2.8*** (2.1-3.5)
Brainfog	6.8 (6.3- 7.4)	2.6*** (1.8- 3.5)	1.3*** (0.9- 1.7)	6.6 (6.0-7.2)	2.5*** (1.5-3.5)	2.1*** (1.5-2.7)
Post exertional malaise†	6.9 (6.3- 7.4)	2.0*** (1.3- 2.7)	0.6*** (0.4- 0.9)	6.0 (5.5-6.6)	2.4*** (1.5-3.3)	2.1*** (1.5-2.7)
Chest pain or chest tightness	15.3 (14.6- 16.1)	5.4*** (4.2- 6.6)	1.4*** (1.0- 1.8)	5.7 (5.1-6.2)	2.8*** (1.8-3.8)	2.5*** (1.9-3.2)
Muscle pain/Joint pain (not sports related)	48.8 (47.8- 49.8)	20.8*** (18.6- 23.0)	5.4*** (4.7- 6.2)	11.8 (11.1-12.6)	9.0** (7.3-10.7)	9.0*** (7.8-10.2)
Palpitations or tachycardia	7.1 (6.6- 7.7)	4.2*** (3.2- 5.3)	2.0*** (1.5- 2.4)	5.8 (5.2-6.4)	3.7** (2.6-4.8)	2.8*** (2.1-3.4)
Confusion	2.9 (2.6- 3.3)	0.8*** (0.4- 1.2)	0.6*** (0.3- 0.9)	2.9 (2.5-3.3)	1.2** (0.5-1.9)	0.5*** (0.2-0.9)
Sleep problems	18.7 (17.9- 19.5)	14.3*** (12.5- 16.1)	7.3*** (6.4- 8.2)	11.8 (11.0-12.6)	10.3 (8.5-12.0)	6.1*** (5.1-7.1)
ringing ears	12.5 (11.9- 13.2)	8.4*** (6.9- 9.8)	4.8*** (4.1- 5.6)	7.7 (7.1-8.3)	6.2 (4.9-7.5)	5.7*** (4.7-6.7)
Dizziness	19.6 (18.8- 20.4)	8.7*** (7.3- 10.1)	2.7*** (2.1- 3.3)	6.1 (5.5-6.7)	4.8 (3.6-6.0)	3.7*** (2.9-4.6)
General malaise	42.0 (41.0- 43.0)	30.0*** (27.5- 32.4)	2.6*** (2.1- 3.2)	6.1 (5.5-6.7)	5.0 (3.7-6.3)	4.4*** (3.6-5.3)
Tingling or numbness	4.4 (4.0- 4.8)	2.2*** (1.4- 2.9)	1.6*** (1.2- 2.0)	4.1 (3.6-4.5)	3.0 (2.0-3.9)	1.7*** (1.1-2.2)
Headache	66.1 (65.1- 67.0)	42.5*** (39.9- 45.1)	14.7*** (13.6- 15.9)	20.2 (19.2-21.1)	19.1 (16.8-21.4)	17.1*** (15.5-18.6)
Shivers	47.6 (46.5- 48.6)	21.5*** (19.3- 23.7)	1.8*** (1.4- 2.3)	5.2 (4.6-5.7)	4.3 (3.1-5.6)	4.4 (3.6-5.3)
Mucus from throat or nose	32.2 (31.3- 33.2)	35.7** (33.2- 38.2)	5.9*** (5.1- 6.8)	6.9 (6.3-7.5)	6.2 (4.8-7.7)	6.9 (5.8-8.0)
Fever	44.7 (43.7- 45.7)	20.7*** (18.5- 22.9)	1.2*** (0.8- 1.5)	2.4 (2.0-2.8)	1.9 (1.1-2.8)	3.6## (2.8-4.4)
Earache	11.1 (10.5- 11.7)	7.6*** (6.2- 9.1)	1.2*** (0.8- 1.6)	2.0 (1.6-2.3)	1.6 (0.8-2.3)	1.6 (1.0-2.1)
Anxiety†	1.7 (1.4- 2.0)	1.0* (0.5- 1.6)	1.6 (1.1- 2.0)	2.2 (1.9-2.6)	1.8 (1.1-2.6)	1.8 (1.2-2.5)

New onset allergy†	0.0 (0.0- 0.1)	0.0 (0.0- 0.0)	0.1# (0.0- 0.2)	0.4 (0.3-0.6)	0.0 (0.0-0.1)	0.0** (0.0-0.0)
Sore eye	5.9 (5.4- 6.3)	4.6 (3.5- 5.8)	1.1*** (0.7- 1.5)	2.2 (1.9-2.6)	1.9 (1.1-2.6)	0.9*** (0.5-1.3)
Winter toes	1.5 (1.3- 1.8)	0.6 (0.2- 0.9) **	0.9** (0.5- 1.2)	1.5 (1.2-1.8)	1.1 (0.5-1.7)	1.1 (0.6-1.5)
Decreased appetite	29.2 (28.3- 30.2)	11.5 (9.8- 13.2)	1.7*** (1.2- 2.1)	2.9 (2.5-3.3)	2.5 (1.6-3.5)	2.1 (1.5-2.8)
Menstruation problems†	1.2 (1.0- 1.5)	0.9 (0.4- 1.4)	1.6 (1.2- 2.0)	2.8 (2.4-3.2)	2.5 (1.5-3.4)	1.7** (1.1-2.2)
Rash	2.3 (2.0- 2.6)	1.8 (1.2- 2.5)	1.6*** (1.1- 2.0)	2.4 (2.0-2.7)	2.3 (1.4-3.2)	2.4 (1.7-3.1)
Nausea	13.9 (13.2- 14.6)	9.7*** (8.1- 11.3)	2.6*** (2.0- 3.1)	4.1 (3.6-4.5)	4.0 (2.9-5.1)	3.3 (2.5-4.1)
Depression†	1.0 (0.8- 1.2)	1.6 (0.9- 2.2)	1.8## (1.3- 2.2)	2.6 (2.2-2.9)	2.7 (1.7-3.6)	1.9* (1.3-2.5)
Nosebleed	2.2 (1.9- 2.5)	2.5 (1.6- 3.3)	0.8*** (0.5- 1.1)	1.4 (1.1-1.7)	1.6 (0.8-2.3)	1.1 (0.7-1.6)
Neuralgia	1.1 (0.9- 1.3)	0.5* (0.1- 0.8)	0.8 (0.5- 1.1)	1.1 (0.9-1.4)	1.5 (0.8-2.1)	1.4 (0.9-2.0)
Vomiting	2.6 (2.3- 2.9)	1.8 (1.0- 2.6)	0.6*** (0.3- 0.8)	0.6 (0.4-0.8)	1.0 (0.5-1.6)	0.7 (0.3-1.0)
Altered stool	15.0 (14.2- 15.7)	8.2 (6.8- 9.6)	2.1*** (1.6- 2.6)	4.4 (3.9-4.9)	5.0 (3.6-6.3)	3.1* (2.4-3.9)
Sore throat	51.2 (50.2- 52.2)	70.1### (67.7- 72.4)	7.7*** (6.8- 8.6)	9.9 (9.2-10.6)	10.5 (8.6-12.3)	11.3* (10.0-12.7)
Coughing	75.7 (74.9- 76.6)	64.4*** (61.9- 66.9)	10.1*** (9.0- 11.1)	10.7 (10.0-11.5)	12.0 (10.1-13.9)	13.2## (11.8-14.7)
Abdominal pain	9.6 (9.0- 10.2)	7.0*** (5.6- 8.3)	3.1*** (2.5- 3.7)	3.7 (3.3-4.2)	5.1 (3.7-6.4)	2.9# (2.2-3.7)
Runny nose	82.3 (81.5- 83.1)	76.1*** (73.9- 78.4)	17.3** (16.0- 18.6)	20.1 (19.1-21.0)	21.8 (19.4-24.3)	18.7 (17.1-20.3)
Sneezing	67.1 (66.1- 68.1)	58.7*** (56.0- 61.3)	12.0** (10.9- 13.2)	12.6 (11.8-13.4)	17.9 (15.6-20.2)###	13.6 (12.2-15.1)
Severity cutoff scores						
CIS, subscale fatigue, ≥35	52.7 (51.7-53.7)	31.4 (29.0-33.8)***	12.8 (11.7-13.9) ***	27.5 (26.5-28.6)	18.9*** (16.7-21.2)	15.4*** (14.0-16.9)
CFQ, ≥44	9.8 (9.2-10.4)	10.0 (8.4-11.6)	7.3 (6.4-8.1) ***	15.3 (14.4-16.1)	9.7*** (7.9-11.4)	7.4*** (6.3-8.5)
SF-36 subscale bodily pain, ≤55	9.8 (9.2-10.4)	8.3 (6.9-9.7)	4.8 (4.1-5.5) ***	7.1 (6.5-7.7)	6.3 (4.9-7.7)	6.7 (5.6-7.7)
mMRC, ≥1	17.2 (16.4-17.9)	9.8 (8.3-11.3) ***	2.2 (1.7-2.7) ***	12.6 (11.8-13.3)	4.7*** (3.6-5.8)	4.6*** (3.7-5.6)

Standardised prevalence (95% confidence intervals) of participants with symptoms at T0 and T3 for cases, test-negative controls and population controls using complete analysis without substituting for missing values at T3. Negative values were truncated at 0.

* BH.adjusted p-value <0.05 compared to cases, prevalence higher in cases than in controls

** BH.adjusted p-value <0.01 compared to cases, prevalence higher in cases than in controls

*** BH.adjusted p-value <0.001 compared to cases, prevalence higher in cases than in controls

BH.adjusted p-value <0.05 compared to cases, prevalence lower in cases than in controls

BH.adjusted p-value <0.01 compared to cases, prevalence lower in cases than in controls

BH.adjusted p-value <0.001 compared to cases, prevalence lower in cases than in controls

† Data collected on symptom at T0 only for part of the participants

Bold rows: significant difference between cases and both control groups.

CIS: Checklist Individual Strength

CFQ: Cognitive Failure Questionnaire

SF-36: SF-36 item Health Survey
mMRC: Modified Medical Research Council dyspnoea scale




Figure S1: prevalence of any symptom significantly elevated in cases compared to controls per scenario. For complete case analysis scenario: n cases: 6614, Test-negative controls: 1330, Population controls: 2445; other scenarios: n cases: 9116, Test-negative controls: 1698 Population controls: 3708. Post exertional malaise and problems with memory were not assessed at T0 and could not be used to predict their prevalence at T3 for the multiple imputation and the carrying forward scenario which may have led to an underestimation of reported prevalence of any symptom significantly elevated in these scenarios.




Figure S2: Development of symptoms that are present at T3, i.e. present at T3 and T0 (persistent from T0 onwards), or present at T3 but not at T0 (late onset after T0) for cases per symptom. Post exertional malaise and problems with memory were not assessed for all cases at T0 and are omitted from this figure.




Figure S3. Standardised prevalence (95% confidence intervals) of participants with symptoms at T3 for cases <65 that were fully, partially or unvaccinated. Complete analysis without substituting for missing values at T3. * BH.adjusted p-value <0.05 compared to vaccinated cases, prevalence higher in unvaccinated cases; ** BH.adjusted p-value <0.01 compared to vaccinated case, prevalence higher in unvaccinated cases




Figure S4: standardized prevalence of any symptom significantly elevated at T3. Cases <65 that were fully, partially or unvaccinated using complete analysis without substituting for missing values at T3




Figure S5. Standardised prevalence (95% confidence intervals) of participants with symptoms at T0 for cases <65 years old that were fully, partially or unvaccinated. * BH.adjusted p-value <0.05 compared to vaccinated case, prevalence higher in unvaccinated cases; ** BH.adjusted p-value <0.01 compared to vaccinated case, prevalence higher in unvaccinated cases; *** BH.adjusted p-value <0.001 compared to vaccinated case, prevalence higher in unvaccinated cases; # BH.adjusted p-value <0.05 compared to vaccinated case, prevalence lower in unvaccinated cases; ### BH.adjusted p-value <0.01 compared to vaccinated case, prevalence lower in unvaccinated cases; #### BH.adjusted p-value <0.001 compared to vaccinated case, prevalence lower in unvaccinated cases

Table S3: Demographics and acute illness at baseline stratified by vaccination status

	Fully vaccinated	Partially vaccinated	Unvaccinated
n	8,058	1,771	993
Demographics			
Age, median [range]	51.7 [40, 63]	40.9 [29, 49]	37.8 [27, 53]
Sex, % (n)			
F	62.6 (5048)	63.8 (1130)	71.6 (711)
M	37.2 (2994)	35.7 (633)	28.1 (279)
other	0.2 (16)	0.5 (8)	0.3 (3)
Pregnancy, % (n)	2.6 (59)	1.4 (10)	4.9 (25)
BMI, mean (SD)	26.09 (4.79)	24.99 (4.40)	24.88 (4.45)
Smoking, % (n)			
Current smoker	5.2 (423)	5.8 (103)	6.9 (69)
Former smoker	26.2 (2110)	18.3 (324)	19.4 (193)
Never smoker	65.7 (5297)	70.7 (1252)	68.1 (676)
Level of education, % (n)			
Low	3.8 (305)	1.1 (20)	3.1 (31)
Median	36.7 (2961)	34.8 (617)	46.0 (457)
High	59.5 (4792)	64.0 (1134)	50.9 (505)
History with COVID-19, % (n)	9.3 (753)	2.3 (40)	17.4 (173)
Nr of comorbidities, % (n)			
0	45.1 (3634)	60.6 (1074)	57.0 (566)
1-2	43.6 (3511)	33.9 (600)	34.4 (342)
>2	11.3 (913)	5.5 (97)	8.6 (85)
Respiratory disease, % (n)**	18.0 (1449)	11.6 (205)	13.4 (133)
Hypertension, % (n)	12.7 (1020)	5.4 (96)	4.8 (48)
Diabetes, % (n)	3.6 (288)	0.8 (14)	0.8 (8)
Cardiovascular disease, % (n)***	2.2 (174)	0.5 (8)	0.2 (2)
Use of healthcare, % (n)*	10.1 (815)	8.9 (158)	15.5 (154)
Medication use, % (n)*	77.0 (6206)	76.1 (1348)	76.9 (764)
Admitted to hospital, % (n)*	0.1 (4)	0.1 (1)	0.6 (6)
Vaccine type % (freq)			
AstraZeneca	19.9 (1601)	2.3 (41)	NA
CureVac	0.0 (0)	0.1 (1)	NA
Janssen	0.1 (9)	51.8 (916)	NA
Moderna	7.5 (606)	3.4 (60)	NA
Pfizer	67.2 (5413)	38.1 (674)	NA
combination	5.2 (418)	4.1 (72)	NA
unknown	0.1 (11)	0.2 (3)	NA

References:

1. Hothorn TH, K.; van de Wiel, M.A.V.; Zeileis, Al. Implementing a Class of Permutation Tests: The coin Package. *J Stat Softw.* 2008; **28**(8): 1-23.
2. Ferreira JA. Some models and methods for the analysis of observational data. *Statistics Surveys.* 2015; **9**: 106-208.
3. Ernst MD. Permutation Methods: A Basis for Exact Inference. *Statist Sci.* 2004; **19**(4): 676-85.
4. van Buuren SG-O, K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software.* 2011; **45**(3): 1-67.